Posts tagged healthcare system
BioLight’s CellDetect posts positive results in prostate cancer

BioLight Life Sciences (TASE:BOLT) reported promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology.

The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage.

Read More
HCW assumes coverage of Vical at buy

H.C. Wainwright analyst Shaunak Deepak assumed coverage of Vical (NASDAQ:VICL) with a “buy” rating and $12 price target. The stock was quoted at $4.39, up 3 cents, Tuesday afternoon.

“With a co-marketable asset in Phase 3 development that is fully funded by partner, Astellas, and a diversified clinical pipeline, we believe Vical should be trading above cash,” Mr. Deepak writes.

Read More